

Judith Neukirchen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3282477/publications.pdf>

Version: 2024-02-01

17
papers

593
citations

933447

10
h-index

940533

16
g-index

17
all docs

17
docs citations

17
times ranked

872
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry. <i>Leukemia Research</i> , 2011, 35, 1591-1596.	0.8	169
2	Improved survival in MDS patients receiving iron chelation therapy – A matched pair analysis of 188 patients from the Düsseldorf MDS registry. <i>Leukemia Research</i> , 2012, 36, 1067-1070.	0.8	115
3	Validation of the revised International Prognostic Scoring System (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. <i>Leukemia Research</i> , 2014, 38, 57-64.	0.8	68
4	Platelet counts and haemorrhagic diathesis in patients with myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2009, 83, 477-482.	2.2	63
5	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	7.2	54
6	Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2015, 95, 181-189.	2.2	27
7	Change of prognosis of patients with myelodysplastic syndromes during the last 30 years. <i>Leukemia Research</i> , 2015, 39, 679-683.	0.8	19
8	Cytogenetic clonal evolution in myelodysplastic syndromes is associated with inferior prognosis. <i>Cancer</i> , 2017, 123, 4608-4616.	4.1	18
9	A retrospective study evaluating the impact of infectious complications during azacitidine treatment. <i>Annals of Hematology</i> , 2017, 96, 1097-1104.	1.8	15
10	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	1.3	15
11	Iron chelation in MDS: Still a controversial issue. <i>Leukemia Research</i> , 2014, 38, 145-146.	0.8	10
12	Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow. <i>Annals of Hematology</i> , 2014, 93, 65-69.	1.8	8
13	Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients. <i>Annals of Hematology</i> , 2021, 100, 2575-2584.	1.8	5
14	Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center. <i>Leukemia Research</i> , 2021, 108, 106611.	0.8	4
15	Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations. <i>Cancers</i> , 2022, 14, 2147.	3.7	2
16	Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 3700-3700.	1.4	1
17	Prognostic molecular markers in myelodysplastic syndromes. <i>Expert Review of Hematology</i> , 2009, 2, 563-575.	2.2	0